TGFBI Promoter Hypermethylation Correlating With Paclitaxel Chemoresistance in Ovarian Cancer

Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/1756-9966-31-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CD44-targeted PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer

Cancer Research
Cancer ResearchOncology
2018English

Clinical Trials and Progress With Paclitaxel in Ovarian Cancer

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2010English

Chemoresistance‑associated Alternative Splicing Signatures in Serous Ovarian Cancer

Oncology Letters
Cancer ResearchOncology
2020English

Fibulin 1 Is Downregulated Through Promoter Hypermethylation in Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2008English

Leptin Contributes to the Taxol Chemoresistance in Epithelial Ovarian Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Evaluation of the Efficacy of Paclitaxel With Curcumin Combination in Ovarian Cancer Cells

Oncology Letters
Cancer ResearchOncology
2016English

Emodin Sensitizes Paclitaxel-Resistant Human Ovarian Cancer Cells to Paclitaxel-Induced Apoptosis in Vitro

Oncology Reports
MedicineCancer ResearchOncology
2009English

The Expression and Promoter Hypermethylation Status of MGMT, RASSF1A in Gastric Cancer

World Journal of Cancer Research
2014English

MAPT Promoter CpG Island Hypermethylation Is Associated With Poor Prognosis in Patients With Stage II Colorectal Cancer

Cancer Management and Research
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy